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Abstract 
Purpose: High cholesterol levels have been directly linked to atherosclerosis, which is a leading 
cause of cardiovascular disease (CVD). Risk factors that accelerate the development of 
atherosclerosis, such as high cholesterol can begin in childhood. The purpose of this project was 
to evaluate provider adherence to the National Heart, Lung, and Blood Institute’s (NHLBI) 
Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, 
specifically the guidelines on universal lipid screening in children aged 9-11 years.  The 
objectives were: 1) determine the rate of lipid screening in children 9-11 years old; 2) determine 
the number of children who meet the criteria for the diagnosis of dyslipidemia; and 3) determine 
the method of treatment of children diagnosed with dyslipidemia.  
Method: The setting was a pediatric clinic in a large healthcare organization in the Midwest. A 
retrospective chart review was performed on 97 randomly selected charts of patients ages 9 to 11 
years old who were seen in the clinic for a well-child exam from February 1, 2018 through July 
31, 2018.   
Results:  The majority of patients were 11 years old (49.5%), male (55.7%), and white (84.5%).  
Providers ordered lipid panels 47.4% of the time.  Abnormal results were found in 44.2% of 
patients and additional testing was ordered in 26.3% of those patients which were outside 
recommended guideline parameters.  No patients met the criteria for a diagnosis of 
hypercholesterolemia according to the guideline recommendations. 
Conclusion:  Providers in this clinic were not consistently following recommended NHLBI 
guidelines regarding lipid panel screening in the pediatric population.  Providers were more 
likely to perform lipid panels on patients who are 11 years old and male.   There is an 
opportunity to improve lipid screening rates in the pediatric population in an effort to prevent the 
development of cardiovascular disease in later life.  Educating providers on the NHLBI’s 
recommended guidelines for practice may improve screening rates and identification of those at 
risk.
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Introduction 
One-third of the world’s cases of cardiovascular disease are related to high cholesterol 
and an estimated 2.6 million deaths will be caused by hypercholesterolemia globally in 2018 
(World Health Organization [WHO], 2018). In 2018, the WHO reported that the United States 
(US) had the second highest prevalence of high cholesterol levels in the world at 48%, with 
Europe coming in first at 54% (WHO, 2018). The Centers for Disease Control and Prevention 
(CDC) report that from 2011-2014, 95 million Americans over the age of 20 years had high total 
cholesterol levels (U.S. Department of Health and Human Services [HHS], 2017a). During those 
same years, an astounding number of children and adolescents, as many as 1 of every 5, had at 
least one high cholesterol level (Nguyen, Kit, & Carroll, 2015). The National Health and 
Nutrition Examination Survey (NHANES) data collected during the years 1998-2010 showed 
that 24.6% of children between the ages of 9-11 years had an elevated non-high-density-
lipoprotein cholesterol (non-HDL-C) level or an abnormally low HDL-C (Valle, Binns, Quadri-
Sheriff, Benuck, & Patel, 2015).  High cholesterol is linked to atherosclerosis which is a leading 
cause of cardiovascular disease. In 2012, the National Heart, Lung, and Blood Institute (NHLBI) 
developed an expert panel to conduct a study and make recommendations in an effort to reduce 
the risk of developing cardiovascular disease in children and adolescents. The purpose of this 
project was to assess provider adherence to the National Heart, Lung, and Blood Institute’s 
guidelines on universal lipid screening in children aged 9-11 years.   
Background 
High cholesterol levels have been directly linked to atherosclerosis, which is a leading 
cause of cardiovascular disease (CVD) and stroke. Atherosclerosis afflicts an estimated 1.5 
million Americans every year and costs approximately $316.6 billion annually (HHS, 2011). 
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Atherosclerosis progresses slowly beginning with the abnormal accumulation of lipids in the 
vascular intima forming an innocuous lesion called a fatty streak.  This fatty streak, if left 
untreated, progresses to a fibrous plaque with the potential to rupture or occlude the lumen 
culminating in thrombosis, vascular dissection, or acute ischemic syndrome (HHS, 2012).  
Researchers from two different studies identified the presence of atherosclerotic lesions in the 
aortic and coronary arteries at autopsy of children and young adults who had died of various 
causes (Berenson, Srinivasan, Bao, Newman, Tracy, & Wattigney, 1998; Strong, Malcom, 
McMahan, Tracy, Newman, Herderick, & Cornhill, 1999).  These studies suggest that the 
behaviors leading to atherosclerosis begin in childhood; therefore, early intervention to reduce 
cardiovascular risk should begin early in the life cycle.  
Based on the scientific evidence review of cardiovascular risk factors and the 
development of atherosclerosis in childhood, the NHLBI expert panel concluded that early 
identification and intervention of hypercholesterolemia in childhood could significantly reduce 
CVD risk in adulthood (HHS, 2012). Therefore, the NHLBI, with the endorsement of the 
American Academy of Pediatrics (AAP), developed cholesterol screening guidelines strongly 
recommending primary care providers (PCP) begin performing universal lipid screening (fasting 
or non-fasting) in children aged 9-11 years (HHS, 2012).  
Targeted values for a fasting lipid panel in children are low-density lipoprotein 
cholesterol (LDL-C) < 130 mg/dL, non-HDL-C less than 145 mg/dL, and HDL-C greater than 40 
mg/dL.  The targeted value for triglycerides (TG) for children under age 10 is less than 100 
mg/dL or less than 130 mg/dL if 10 years or older (HHS, 2012). The NHLBI’s expert panel 
strongly recommends screening be performed using a non-fasting lipid panel (non-FLP) and then 
calculating the non-HDL-C by subtracting the HDL-C from the total cholesterol (TC) (HHS, 
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2012). The expert panel found that the non-HDL-C is a better predictor of CVD risk later in life 
(HHS, 2012).   
In a study tracking children into adulthood over a 27-year period, children with high non-
HDL-C levels were found to be 4.5 times more likely to develop dyslipidemia in adulthood, 
whereas children with high LDL-C levels were 3.5 times more likely to develop dyslipidemia in 
adulthood (Srinivasan, Frontini, Xu, & Berenson, 2006).  Srinivasan and colleagues (2006) also 
revealed elevated levels of non-HDL-C in childhood can predict adulthood hyperglycemia, 
hyperinsulinemia, and low-HDL-C levels.  High levels of non-HDL-C in childhood has also 
been associated with increased prevalence of obesity, increased triglycerides and LDL-C levels 
(Srinivasan, Frontini, Xu, & Berenson, 2006). 
An abnormal non-FLP results when a non-HDL-C level is greater than or equal to 145 
mg/dL and an HDL-C is less than 40mg/dL (HHS, 2012). For children with an abnormal non-
FLP the NHLBI panel recommends obtaining two FLP’s within two weeks to three months apart 
(HHS, 2012). Abnormal results should be evaluated for secondary causes and risk factors to 
determine the best intervention which may include lifestyle changes and/or pharmacological 
treatment (HHS, 2012).  The NHLBI developed algorithms to assist in determining the course of 
treatment dependent upon LDL-C (Figure 1) and TG (Figure 2) levels.  Addressing CVD risk 
factors in childhood may reduce the risk of developing lifelong chronic disease in adulthood 
leading to a longer, healthier life.    
Universal cholesterol screening is the recommended and preferred method of 
hypercholesterolemia identification in the pediatric population aged 9-11 years (HHS, 2012). 
The screening can be performed in the primary care office during a well-child visit. Universal 
screening can identify more cases of hypercholesterolemia than considering familial or 
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individual risk factors, such as familial hypercholesterolemia, obesity, and diabetes, to determine 
the need for cholesterol screening. For example, using the universal screening method in children 
has proven to identify 30-60% more hypercholesterolemia cases in children allowing for early 
intervention and decreasing mortality and morbidity rates in adulthood (Wilson et al., 2015). 
These results support using universal cholesterol screening in the primary care office as a first 
line strategy to identify children at risk for CVD. 
de Ferranti and colleagues (2017) surveyed 1,627 U.S. pediatricians to determine 
screening practices of providers and to identify any barriers to recommended practice.  Over half 
(68%) of pediatricians did not universally screen children 9 to 11 years old.  More providers 
screened based on family history and obesity. In addition, pediatricians were more likely to 
screen older children than younger.  Lack of knowledge of guidelines was identified as one 
barrier with only 26% of providers surveyed expressing familiarity with current NHLBI 
guidelines. Nearly all pediatricians surveyed provided lifestyle modification education. While 
some pediatricians identified interpretation of cholesterol profile as a barrier (35%), a higher 
percentage identified patients not returning for a fasting lipid test (89%), and inability to obtain 
an accurate family history (60%) (de Ferranti et al., 2017).  The advent of the electronic health 
record (EHR) has offered the potential for enhanced decision support and reminders which could 
increase provider adherence to universal screening guidelines (DeSantes, Dodge, Eickoff, & 
Peterson, 2017).   
Research shows that providers are not consistently following the NHLBI guidelines.  
DeSantes and colleagues (2017) performed a retrospective review of EHRs in a pediatric practice 
in an academic health center to determine if publication of the NHLBI guidelines on pediatric 
lipid screening changed practice of universal screening.  Records of 22,374 patients from 
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January 2010 to December 2015 were reviewed. The researchers found screening orders 
increased from 8.9% before publication of the guideline to a high of 60.9% after publications. 
Lipid screening was ordered more often for older children 17 to 21 years old (45.5%) than 
younger children 9 to 11 years old (32.5%).  There was no difference in screening orders 
between males and females. The researchers attributed the increase in screening orders to 
publication of the guidelines, provider education and EHR modifications.  Mihalopoulis and 
colleagues (2018) analyzed data from two large health care systems and an insurance company to 
evaluate provider adherence to universal screening guidelines for children 9 to 11 years old.  A 
lipid screening test was obtained for 3.5% of the 63,951 patients seen for well child visits during 
the study period.  Of those screened, 43% had an abnormal result.   
Valle and colleagues (2015) found slightly better adherence to the guidelines in their 
retrospective review of medical records of 298 children.  When comparing screening rates before 
and after publication of the NHLBI guidelines, the researchers found 12.4% of the 298 children 
were screened prior to publication and 16.9% of the remaining 261 children were screened after 
publication.   
Purpose and Objectives 
The overall goal of this project was to assess provider adherence to the National Heart, 
Lung, and Blood Institute’s (2012) guidelines on universal lipid screening in children aged 9-11 
years in a pediatric practice in a large healthcare organization.  More specifically the following 
objectives were explored: 
1. Determine the rate of lipid screening in children 9-11 years old. 
2. Determine the number of children who meet the criteria for the diagnosis of 
dyslipidemia. 
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3. Determine the method of treatment of children diagnosed with dyslipidemia.  
Setting 
 The setting was a pediatric clinic within a large healthcare organization in the Midwest.  
This organization serves patients all across the life span, but for purposes of this study the focus 
was on patients aged 9-11 years.   
Methods 
A retrospective chart review of 97 randomly selected patient charts was performed to 
determine current practice regarding dyslipidemia screening, diagnosis, and treatment in the 
pediatric population aged 9-11 years.  The health care organization’s information technology 
(IT) department utilized inclusion criteria to obtain chart information for the population of 
interest. That data was analyzed to determine if lipid screening is being performed per NHLBI 
recommended guidelines.  A further detailed manual review of the patient chart determined if the 
provider documented a discussion regarding why or why not lipid screening was performed.  In 
addition, the manual chart review consisted of reviewing risk factors, family history, lab results 
and provider documentation.   
Sample 
A data information request was provided to the healthcare organization to obtain records 
for evaluation.  Inclusion criteria were any patient between the ages of 9-11 years old having a 
well child visit using ICD-10 code Z00.129 during February 1, 2018 and July 31, 2018.  The 
healthcare organization IT department provided a list of patients meeting the inclusion criteria 
from the approved pediatric clinic with a sample goal of 100 charts to be studied.  The initial 
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data compilation returned 326 patient charts.  The 100 charts included in this study were 
randomly selected from the 326 charts.  
Informed Consent 
This project involved a retrospective chart review therefore informed consent was not 
practical.  A waiver of documentation of informed consent was requested and granted by the 
University of Kentucky Institutional Review Board and the healthcare organization’s research 
office.  
Procedure 
  A crosswalk table was constructed providing the only link between the patient’s medical 
record number to a unique study identifier thus ensuring confidentiality of the chart information.  
The crosswalk table and the data collection files were saved in separate locations on the 
healthcare organization’s secured drive that is firewall protected.  Charts were evaluated for well 
child visit ICD-10 code Z00.129 and CPT code 80061 for lipid panel.  If a lipid panel was 
completed then the results and the provider’s documentation of acknowledgement of results as 
well as treatment ordered were reviewed.  If a lipid panel was not completed, the provider notes 
were reviewed for explanation.  Provider documentation was compared to NHLBI recommended 
guidelines to determine adherence.  Charts were also reviewed to determine patient compliance 
with additional testing requirements, when appropriate, within the time frame of the study.   
Data Analysis 
 Descriptive statistics with frequency intervals were used to determine provider adherence 
to NHLBI recommended guidelines for universal lipid screening in the pediatric population aged 
9-11 years.  Frequency intervals were also used to determine how often a diagnosis of 
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hypercholesterolemia was made and a treatment recommended.  A chi-square test for 
independence was performed to determine significant differences in lipid screening for gender, 
age and race with an alpha level of p < .05.   
Results 
 Of the 100 charts randomly selected, 3 charts were found to not include the well child 
visit code Z00.129; therefore, those charts were excluded from the sample, decreasing the sample 
size to 97.  Of the remaining 97 well visit charts reviewed, the majority of the patients were aged 
11 years (49.5%), followed by aged 10 years (28.9%), then aged 9 years (21.6%).The majority of 
the sample was male (55.7%) and White (84.5%) (see Table 1).   During the well child visit a 
lipid panel was ordered and completed for 44.3%, ordered and not completed 3.1%, and not 
ordered 52.6% (see Table 2).  Of those with a completed lipid panel none met criteria to require 
further lipid testing as outlined in the NHLBI guidelines.  Of the lipid panels performed only one 
had a non-HDL-C greater than 145 but the HDL-C was greater than 40 excluding the need for 
further testing.   
Providers interpreted lipid panels as being abnormal in 44.2% of the sample and ordered 
additional testing in 26.3% of that sample.  These results were outside recommended guideline 
parameters and therefore should not have been reported as abnormal and did not require 
additional testing.  Two patients had abnormal non-fasting lipid panels and were subsequently 
diagnosed with hypercholesterolemia even though they did not meet the guideline’s criteria for 
the diagnosis.    The results of the chi-square test for gender (p = .013) indicate there was a 
statistically significant relationship between gender and lipid panels being performed at well 
child visits. Boys were more likely to be screened than girls. There was also a statistically 
significant relationship between age and whether a lipid panel was performed (p < .001). Patients 
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who were 11 years old were more likely to have a lipid panel performed than younger patients. 
There was no statistical significance between race and whether or not a lipid panel was 
performed (p = .602; See Table 3).  
Data was collected on risk factors for cardiovascular disease such as hypertension, 
obesity, and family history in addition to lipid levels (See Table 4).  According to the 
hypertension guidelines provided by the American Academy of Pediatrics (Flynn et al., 2017), 
24 male patients (44%) and 22 female patients (51%) met the criteria for elevated blood pressure.  
Of those patients meeting hypertension criteria, 17 males (71%) and 8 females (36%) had lipid 
panels ordered.   
Obesity in the pediatric population is defined by the CDC to be a body mass index (BMI) 
greater than the 95th percentile of the CDC sex and age specific growth chart (HHS, 2018; HHS, 
2000).  Using the data from these growth charts, 11 males (20%) and 15 females (35%) met 
obesity criteria.  Lipid panels were drawn on 5 of the obese males (45%) and on 6 of the obese 
females (40%).  Some patients met criteria for both hypertension and obesity.  Of the sample, 6 
males (11%) and 13 females (30%) met those criteria and lipid panels were ordered on 3 of those 
male patients (50%) and 5 of the female patients (38%).   
Family history was reviewed for cardiovascular risk factors such as diabetes, heart 
disease, hyperlipidemia, hypertension, and stroke.  A positive family history was determined if 
one of these risk factors were reported on a child’s mother, father, or grandparents.  At least one 
risk factor was reported in 74 patients (76%), 37 males (50%) and 37 females (50%) with lipid 
panels being ordered on 25 of those male patients (68%) and 16 of those female patients (43%).   
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In an attempt to find a correlation between lipid testing in relation to insurance coverage, 
data collected showed 75% of the patients had commercial insurance, 24% had government 
issued insurance coverage, and 1% had no insurance coverage (See Table 5).  The patients with 
commercial insurance had lipid panels ordered 49% of the time whereas patients with 
government issued insurance was 44%.  Under commercial insurance, children 11 years of age 
had a lipid panel ordered 87% of the time regardless of gender, with males slightly more often at 
89% than females at 82%.  Of the 19 children aged 9 with commercial insurance, none had 
orders for a lipid panel and only 13% of 10-year-olds received lipid panel orders, 1 male and 1 
female. Under government issued insurance 11-year-old children received orders for a lipid 
panel 78% of the time regardless of gender, with males at 67% and females at 100%.  Of the 4 
children aged 9 with government issued insurance none had orders for a lipid panel and only 
30% of the 10-year-olds received lipid panel orders, all female.  These data show that children 
aged 11, regardless of insurance carrier, had a higher percentage of lipid panels ordered than 
those 9-10 years of age.  Males had higher percentages of lipid panel orders under both types of 
insurance. 
In 100% of the sample lifestyle modification was discussed in the form of diet and 
exercise. Each patient was counseled on eating a balanced diet with meats, fish, vegetables, fruit, 
and healthy snacks.  Patients were encouraged to limit junk food and eat low fat dairy products 
including low fat milk.  Education was provided on drinking mostly water with the occasional 
sports drinks, soft drinks, juice, and sweet tea.  Each child was encouraged to limit screen time 
and get plenty of exercise, although no specific information was documented as to how much 
exercise weekly or how long to exercise.   
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Discussion 
 The results of this study show that providers in this pediatric clinic are not 
consistently ordering universal lipid screening on pediatric patients between the ages of 9-11 
years.  In addition, these data show that these providers are ordering universal lipid screening, 
according to NHLBI guidelines, only 47.4% of the time.  This rate is much higher than other 
studies found which show providers performing universal screening at much lower rates, such as 
3.5% and 3.2% (Mihalopoulis et al., 2018; Wilson et al., 2018). Other studies have found a 
higher compliance of screening at a rate of 27.2% (Valle et al., 2015), but still lower rates than 
demonstrated in this study.  This study found these providers were more likely to order lipid 
panels on children who are aged 11 years and male (see Table 3).  These data show that most of 
the children in this study did not meet the criteria for further testing according to the NHLBI 
guidelines resulting in no diagnoses of hypercholesterolemia within the parameters of this study.  
In addition, providers were inconsistent in following guideline recommendations regarding when 
to consider results abnormal and performing further testing.  Some providers ordered additional 
fasting lipid panels outside guideline recommendations.  Lack of provider knowledge concerning 
universal screening recommendations could be a contributing factor to the lower compliance 
rates of this study.   
According to the data collected, no pattern was revealed for ordering of the lipid panels.  
Patients with multiple risk factor criteria were not always tested whereas some without any risk 
factors were tested.  EMR reminders could be used to improve compliance to universal 
cholesterol testing as well as guideline education.   
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Limitations 
Some limitations to this study include small sample size and study participants from only 
one clinic.  The study period for this review was 6 months which did not allow time to see if 
lipid panels had been completed during a different well child visit during ages 9-11 years.  Three 
of the charts reviewed did not contain well child visit ICD-10 code Z00.129.  In addition, 
providers’ charting did not specifically address treatment or rationale for treatment or lack of.  
Also, neither providers nor parents were interviewed to determine barriers to lipid screening.  
Implications for Further Study  
 Further study about this topic should include a wider time span for the collection of data 
and correlation between risk factors and lab testing.  Lipid panel trends could be followed to 
determine if test results improve with lifestyle modification as the only intervention or if 
pharmaceutical treatment is warranted.  Also, following patients into adulthood could provide 
additional information into CVD development among this population.  Additionally, 
interviewing pediatric providers to understand why they are not ordering universal cholesterol 
screening amongst this population, the barriers to testing, and parents’ receptiveness to testing 
and education would provide valuable information. 
Implications for Practice 
 Providers in this pediatric clinic did not follow recommended guidelines for lipid 
screening in the pediatric population.  Lipid screening at an early age has the potential to identify 
early signals for cardiovascular disease later in life.  Screening can identify risk factors and 
provide opportunity for early intervention that can carry over through the life span possibly 
improving patient morbidity, mortality, and overall quality of life. 
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Conclusion 
 Cardiovascular disease is one of the leading causes of death in the United States (HHS, 
2017b).  Early signs of heart disease have been found in young adults in the form of 
atherosclerotic plaques in the coronary arteries and aorta.  Lifestyle modification at an early age 
is expected to decrease cardiovascular disease later in life.  The NHLBI (2012) developed lipid 
screening guidelines for the pediatric population in an effort to decrease the incidence of 
cardiovascular disease in adults.  This study found that providers in this clinic were not following 
recommended guidelines regarding universal lipid screening in the pediatric population aged 9-
11 years.    The results of this study imply there is an opportunity to improve lipid screening rates 
in the pediatric population in an effort to decrease or possibly prevent the development of 
cardiovascular disease later in life.  Educating providers on the NHLBI’s recommended 
guidelines for practice may improve screening rates and the identification of those at risk.    
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Table 1. Demographic characteristics of sample (N = 97) 
Characteristics  n (%) 
Age 
   9 
   10 
   11 
 
21 (21.6%) 
28 (28.9%) 
48 (49.5%) 
Sex 
   Male 
   Female 
 
54 (55.7%) 
43 (44.3%) 
Race/ethnicity 
   White 
   Black 
   Hispanic 
   Unknown 
 
82 (84.5%) 
5 (5.2%) 
8 (8.2%) 
2 (2.1%) 
 
Table 2. Frequency of lipid panel (N = 97) 
Lipid panel ordered/collected n (%) 
   
 Yes, ordered and collected 
 Yes, but not collected  
 No, not ordered 
 
43 (44.3%) 
3 (3.1%) 
51 (52.6%) 
 
Table 3. Demographic characteristics by lipid panel (N = 97) 
Characteristics Completed Ordered but not 
completed 
Not ordered p-value 
Age 
   9 
   10 
   11 
 
0 (0.0%) 
4 (14.3%) 
39 (81.3%) 
 
0 (0.0%) 
1 (3.6%) 
2 (4.2%) 
 
21 (100.0%) 
23 (82.1%) 
7 (14.6%) 
(p = .000) 
Sex 
   Male 
   Female 
 
30 (55.6%) 
13 (30.2%) 
 
0 (0.0%) 
3 (7.0%) 
 
24 (44.4%) 
27 (62.8%) 
(p = .013) 
Race 
   White 
   Black 
   Hispanic 
   Other 
 
37 (45.1%) 
2 (40.0%) 
2 (25.0%) 
2 (100.0%) 
 
3 (3.7%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
42 (51.2%) 
3 (60.0%) 
6 (75.0%) 
0 (0.0%) 
(p = .602) 
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Table 4. Risk Factors for cardiovascular disease (N = 97) 
    
Male 
  
Female 
Lipids Drawn 
Male 
Lipids Drawn 
Female 
HTN 24 (44%) 22 (51%) 17 (71%) 8 (36%) 
Obesity 11 (20%) 15 (35%) 5 (45%) 6 (40%) 
HTN and 
Obesity 
6 (11%) 13 (30%) 3 (50%) 5 (38%) 
FHx 37 (50%) 37 (50%) 25 (68%) 16 (43%) 
 
Table 5. Insurance carrier by lipid panel (N = 97) 
  Lipid Drawn 
Commercial Insurance 
Lipid Drawn 
Government Insurance 
Overall lipid drawn 36 (49%) 10 (44%) 
Age 11 years 34 (87%) 7 (78%) 
Age 10 years 2 (13%) 3 (30%) 
Age 9 years 0 0 
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Figure 1. Dyslipidemia Algorithm Target LDL-C. Reprinted from NHLBI Guidelines (HHS, 
2012). 
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Figure 2. Dyslipidemia Algorithm Target TG. Reprinted from NHLBI Guidelines (HHS, 2012).  
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